^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ezabenlimab (BI 754091)

    i
    Other names: BI 754091, BI754091, BI-754091
    Company:
    Boehringer Ingelheim
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=58, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2027 --> Mar 2027 | Trial primary completion date: Jun 2027 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    6d
    A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=60, Suspended, Boehringer Ingelheim | Recruiting --> Suspended
    Trial suspension
    |
    ezabenlimab (BI 754091)
    14d
    A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: May 2026 --> Sep 2026
    Trial primary completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063 • BI 770371
    15d
    A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab (clinicaltrials.gov)
    P1, N=60, Recruiting, Boehringer Ingelheim
    New P1 trial • First-in-human
    |
    ezabenlimab (BI 754091)
    1m
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=21, Completed, Boehringer Ingelheim | N=97 --> 21 | Trial completion date: Sep 2028 --> Oct 2025 | Trial primary completion date: Jun 2028 --> Aug 2025 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    1m
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Erbitux (cetuximab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    1m
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)
    2ms
    Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy (2025-523575-36-00)
    P1/2, N=160, Not yet recruiting, Cliniques Universitaires Saint-Luc
    New P1/2 trial • Minimal residual disease • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    ezabenlimab (BI 754091)
    2ms
    CAR2BRAIN: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Johann Wolfgang Goethe University Hospital | Active, not recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    ezabenlimab (BI 754091) • HER2 t-haNK
    2ms
    A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab (2025-522953-21-00)
    P1, N=12, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P1 trial
    |
    ezabenlimab (BI 754091)
    2ms
    A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=60, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ezabenlimab (BI 754091)
    2ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=97, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049